Institutional Review Board Grants Approval for Cybin-Sponsored Feasibility Study Using Kernel Flow Technology to Measure… Jan 11, 2022
Awakn Life Sciences Announces Positive Results from Phase II A/B Ketamine-Assisted Therapy for Treatment of Alcohol Use… Jan 11, 2022
Mydecine Achieves Innovative Supercomputing Artificial Intelligence Modeling in Psychedelic Drug Development Enabling… Jan 10, 2022
Field Trip Announces Intention to Make Applications on Behalf of Patients to Health Canada’s Special Access Program… Jan 6, 2022
Health Canada’s Special Access Program Will Now Allow Doctors To Request Patient Access To Psychedelics Jan 5, 2022
Awakn Life Sciences Expands World’s First Ketamine Study Beyond Gambling Disorder to Include Additional Behavioral… Jan 5, 2022
